| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6184220 | AVONDALE PHARMS | Oral suspension of pharmaceutical substance |
Mar, 2019
(5 years ago) | |
|
US6184220 (Pediatric) | AVONDALE PHARMS | Oral suspension of pharmaceutical substance |
Sep, 2019
(4 years ago) | |
Meloxicam is owned by Avondale Pharms.
Meloxicam contains Meloxicam.
Meloxicam has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Meloxicam are:
- US6184220
- US6184220*PED
Meloxicam was authorised for market use on 01 June, 2004.
Meloxicam is available in suspension;oral dosage forms.
The generics of Meloxicam are possible to be released after 25 September, 2019.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Feb 11, 2013 |
| Orphan Drug Exclusivity(ODE) | Aug 11, 2012 |
Drugs and Companies using MELOXICAM ingredient
Market Authorisation Date: 01 June, 2004
Treatment: NA
Dosage: SUSPENSION;ORAL
How can I launch a generic of MELOXICAM before it's drug patent expiration?
More Information on Dosage
MELOXICAM family patents
